Etravirine in Treatment-Experienced Children and Adolescents

PIANO Trial
## Etravirine in Treatment-Experienced Children & Adolescents

### PIANO: Study Design

**Study Design: PIANO**

- **Background**: Phase 2, single-arm trial assessing safety and efficacy of etravirine in treatment-experienced, HIV-infected patients

- **Inclusion Criteria (n = 101)**
  - Children ≥6 and <12
  - Adolescents ≥12 and <18
  - Treatment-experienced
  - No resistance to etravirine

- **Treatment Arms**
  - Etravirine 5.2 mg/kg bid + Investigator-selected optimized background regimen (OBR)

*OBT = ≥ 2 active ARVs, including a ritonavir-boosted PI and NRTIs +/- Enfuvirtide +/- Raltegravir

---

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 24 and 48: Virologic Response (ITT Analysis, N=F)*

![Bar chart showing virologic response at Week 24 and 48 for children and adolescents.](chart)

- **Week 24:**
  - Children (n=41): 59%
  - Adolescents (n=60): 48%
- **Week 48:**
  - Children (n=41): 68%
  - Adolescents (n=60): 48%

*ITT: Intent-to-Treat, N=F: Noncompleter=Failure

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 48: Measures of Adherence

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 48: Adverse Events

Conclusions: “Results with etravirine 5.2 mg/kg bid (with OBR) in this treatment-experienced paediatric population and etravirine 200 mg bid in treatment-experienced adults were comparable. Etravirine is an NNRTI option for treatment-experienced paediatric patients.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.